Starpharma Holdings Limited (SPL.AX)
AUD 0.1
(-1.02%)
AUD 0.1
(-1.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 8.69 Million AUD | -49.64% |
| 2023 | 17.27 Million AUD | -2.87% |
| 2022 | 17.78 Million AUD | 62.57% |
| 2021 | 10.93 Million AUD | 41.1% |
| 2020 | 7.75 Million AUD | 19.93% |
| 2019 | 6.46 Million AUD | 23.5% |
| 2018 | 5.23 Million AUD | -6.65% |
| 2017 | 5.6 Million AUD | -41.68% |
| 2016 | 9.61 Million AUD | 40.88% |
| 2015 | 6.82 Million AUD | 74.51% |
| 2014 | 3.91 Million AUD | 51.47% |
| 2013 | 2.58 Million AUD | -54.03% |
| 2012 | 5.61 Million AUD | 165.7% |
| 2011 | 2.11 Million AUD | -22.37% |
| 2010 | 2.72 Million AUD | -18.67% |
| 2009 | 3.34 Million AUD | -21.59% |
| 2008 | 4.27 Million AUD | -9.14% |
| 2007 | 4.69 Million AUD | 27.11% |
| 2006 | 3.69 Million AUD | 45.91% |
| 2005 | 2.53 Million AUD | 182.02% |
| 2004 | 898.44 Thousand AUD | -38.98% |
| 2003 | 1.47 Million AUD | -7.58% |
| 2002 | 1.59 Million AUD | 43.55% |
| 2001 | 1.1 Million AUD | 456.9% |
| 2000 | 199.28 Thousand AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 8.69 Million AUD | 0.0% |
| 2024 Q2 | 9.48 Million AUD | 0.0% |
| 2024 FY | 8.69 Million AUD | -49.64% |
| 2023 Q4 | 17.27 Million AUD | 0.0% |
| 2023 Q2 | 16.62 Million AUD | 0.0% |
| 2023 FY | 17.27 Million AUD | -2.87% |
| 2022 Q4 | 17.78 Million AUD | 0.0% |
| 2022 Q2 | 12.24 Million AUD | 0.0% |
| 2022 FY | 17.78 Million AUD | 62.57% |
| 2021 Q4 | 10.93 Million AUD | 0.0% |
| 2021 FY | 10.93 Million AUD | 41.1% |
| 2021 Q2 | 8.23 Million AUD | 0.0% |
| 2020 FY | 7.75 Million AUD | 19.93% |
| 2020 Q2 | 8.59 Million AUD | 0.0% |
| 2020 Q4 | 7.75 Million AUD | 0.0% |
| 2019 Q2 | 4.29 Million AUD | 0.0% |
| 2019 Q4 | 6.46 Million AUD | 0.0% |
| 2019 FY | 6.46 Million AUD | 23.5% |
| 2018 Q2 | 4.93 Million AUD | 0.0% |
| 2018 Q4 | 5.23 Million AUD | 0.0% |
| 2018 FY | 5.23 Million AUD | -6.65% |
| 2017 FY | 5.6 Million AUD | -41.68% |
| 2017 Q4 | 5.6 Million AUD | 0.0% |
| 2017 Q2 | 5.26 Million AUD | 0.0% |
| 2016 Q4 | 9.61 Million AUD | 0.0% |
| 2016 Q2 | 6.95 Million AUD | 0.0% |
| 2016 FY | 9.61 Million AUD | 40.88% |
| 2015 FY | 6.82 Million AUD | 74.51% |
| 2015 Q4 | 6.82 Million AUD | 0.0% |
| 2015 Q2 | 4.09 Million AUD | 0.0% |
| 2014 FY | 3.91 Million AUD | 51.47% |
| 2014 Q2 | 3.28 Million AUD | 0.0% |
| 2014 Q4 | 3.91 Million AUD | 0.0% |
| 2013 Q2 | 3.14 Million AUD | 4.51% |
| 2013 Q4 | 2.58 Million AUD | 5.0% |
| 2013 FY | 2.58 Million AUD | -54.03% |
| 2013 Q1 | 3.01 Million AUD | -46.36% |
| 2013 Q3 | 2.45 Million AUD | -21.91% |
| 2012 FY | 5.61 Million AUD | 165.7% |
| 2012 Q4 | 5.61 Million AUD | 0.0% |
| 2011 Q4 | 2.11 Million AUD | 0.0% |
| 2011 FY | 2.11 Million AUD | -22.37% |
| 2010 FY | 2.72 Million AUD | -18.67% |
| 2010 Q4 | 2.72 Million AUD | 0.0% |
| 2009 FY | 3.34 Million AUD | -21.59% |
| 2009 Q4 | 3.34 Million AUD | 0.0% |
| 2008 FY | 4.27 Million AUD | -9.14% |
| 2008 Q4 | 4.27 Million AUD | 0.0% |
| 2007 Q4 | 4.69 Million AUD | 0.0% |
| 2007 FY | 4.69 Million AUD | 27.11% |
| 2006 FY | 3.69 Million AUD | 45.91% |
| 2006 Q4 | 3.69 Million AUD | 0.0% |
| 2005 FY | 2.53 Million AUD | 182.02% |
| 2005 Q4 | 2.53 Million AUD | 0.0% |
| 2004 Q4 | 898.44 Thousand AUD | 0.0% |
| 2004 FY | 898.44 Thousand AUD | -38.98% |
| 2003 Q4 | 1.47 Million AUD | 0.0% |
| 2003 FY | 1.47 Million AUD | -7.58% |
| 2002 FY | 1.59 Million AUD | 43.55% |
| 2002 Q4 | 1.59 Million AUD | 0.0% |
| 2001 Q4 | 1.1 Million AUD | 0.0% |
| 2001 FY | 1.1 Million AUD | 456.9% |
| 2000 FY | 199.28 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -145.529% |
| Acrux Limited | 5.68 Million AUD | -52.945% |
| Actinogen Medical Limited | 1.61 Million AUD | -438.453% |
| AnteoTech Limited | 4.07 Million AUD | -113.434% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -258.426% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -322.924% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -2734.619% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -60.312% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -153.823% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -823.806% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -2260.726% |
| Biome Australia Limited | 5.37 Million AUD | -61.876% |
| Biotron Limited | 737.5 Thousand AUD | -1079.377% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -133.061% |
| BTC Health Limited | 203.94 Thousand AUD | -4164.813% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 32.063% |
| CSL Limited | 27.88 Billion AUD | 99.969% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -4.396% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 69.06% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -642.749% |
| Dimerix Limited | 13.89 Million AUD | 37.393% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -105.668% |
| Hexima Limited | 248.67 Thousand AUD | -3397.808% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -731.848% |
| Immuron Limited | 2.84 Million AUD | -206.211% |
| Immutep Limited | 10.97 Million AUD | 20.78% |
| Imugene Limited | 33.14 Million AUD | 73.756% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -1915.152% |
| Memphasys Limited | 5.59 Million AUD | -55.533% |
| Nanollose Limited | 465.64 Thousand AUD | -1767.955% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 79.66% |
| Noxopharm Limited | 1.28 Million AUD | -574.989% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -10051.372% |
| Nyrada Inc. | 855.63 Thousand AUD | -916.557% |
| Orthocell Limited | 22.08 Million AUD | 60.612% |
| PharmAust Limited | 896.6 Thousand AUD | -870.102% |
| Patrys Limited | 691.36 Thousand AUD | -1158.091% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -142.667% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -434.957% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -274.017% |
| PYC Therapeutics Limited | 10.18 Million AUD | 14.592% |
| Race Oncology Limited | 1.91 Million AUD | -353.866% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 80.534% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 45.273% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 96.512% |
| Tissue Repair Ltd | 1.35 Million AUD | -543.865% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 7.039% |